Sign up
Pharma Capital

VentriPoint Diagnostics receives order for its VMS Plus - from leading cardiac hospital in Toronto

The VMS+ system uses standard 2D echocardiogram images and Artificial Intelligence (AI)
1542031525_heart-bypass-op.jpg
Pictured - major heart surgery

VentriPoint Diagnostics Ltd (CVE:VPT) and its heart analysis technology was boosted again today - as St. Michael's Hospital in Toronto, Canada ordered its VMS Plus system to use it to assess cardiac patients.

The VMS+ system uses standard 2D echocardiogram images and Artificial Intelligence (AI) to show 3D volumes for, significantly, all four chambers of the heart.

READ: VentriPoint Diagnostics reveals that University of Chicago will assess its heart analysis system

This provides medics with a more efficient and cost-effective method for evaluating cardiac volumes and ejection fractions.

The heart is a pump, so when there is a problem, it is not always easy to know where exactly the fault lies, so analysis of each of the four chambers is essential.

Dr Howard Leong-Poi and Dr Chi-Ming Chow are spearheading the VMS+ acquisition.

Leong-Poi is the head of the cardiology division at St. Michael's Hospital and a clinician-scientist in the Keenan Research Centre for biomedical science.

Chow, meanwhile, is the director of the echocardiography lab and has expertise in the development of innovative technologies in the practice of echocardiography.

"We are very pleased to have the interest and commitment from such a high profile cardiac institution in our own backyard," said Desmond Hirson, the president of VentriPoint.

"We believe that our AI technology and product in the hands of Drs. Leong-Poi and Chow will make a valuable difference to patient outcomes."

READ: VentriPoint Diagnostics shares tick higher as it hires new marketing manager

Dr Leong-Poi added: "Artificial intelligence holds a great deal of promise for many clinical imaging applications and we are very excited to participate with this leading-edge technology to more accurately assess cardiac chamber volumes and function by echocardiography."

VentriPoint noted that there were many potential applications for this innovative technology - including assessing ventricular volumes and function after percutaneous valve interventions, and after cancer chemotherapies.

The firm's VMS system is getting some traction at the moment. Last week, it told investors that the University of Chicago's medical centre was to assess the system.

With the recent market clearance from the key FDA, Chicago will be one of the first sites to evaluate and publish on the performance of the VMS+ system compared to MRI for all four cardiac chambers, spearheaded by Dr Roberto Lang, said the company.

Shares in the company pumped up over 21% to $0.20 in Toronto.

Reporting by Giles Gwinnett

[email protected]

Giles_55af4ddca6481.jpg
Why Invest In VentriPoint Diagnostics Ltd.? Read More Here

Register here to be notified of future VPT Company articles
View full VPT profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.